Fulcrum Therapeutics Inc. (FULC)
NASDAQ: FULC
· Real-Time Price · USD
6.64
-0.18 (-2.64%)
At close: Aug 18, 2025, 3:59 PM
6.64
0.00%
After-hours: Aug 18, 2025, 04:10 PM EDT
-2.64% (1D)
Bid | 6.51 |
Market Cap | 359.17M |
Revenue (ttm) | n/a |
Net Income (ttm) | -73.22M |
EPS (ttm) | -1.18 |
PE Ratio (ttm) | -5.63 |
Forward PE | n/a |
Analyst | Buy |
Ask | 6.66 |
Volume | 389,239 |
Avg. Volume (20D) | 698,530 |
Open | 6.83 |
Previous Close | 6.82 |
Day's Range | 6.57 - 7.06 |
52-Week Range | 2.31 - 9.90 |
Beta | 2.47 |
About FULC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FULC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FULC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-2.82%
Fulcrum Therapeutics shares are trading lower foll...
Unlock content with
Pro Subscription
3 weeks ago
+0%
Fulcrum Therapeutics shares are trading higher after the company announced it will present topline results from the 12 mg dose cohort of its Phase 1b PIONEER trial.